Value Proposition: Small molecule Gastrin-releasing peptide receptor (GRPR) antagonists used to treat chronic itch.

Technology Description

Researchers at Washington University in St. Louis have discovered a group of small molecule Gastrin-releasing peptide receptor (GRPR) antagonists to treat chronic itch through oral administration. Currently, most anti-itch drugs on the market only treat the symptoms and not the itch signaling pathway, which makes it challenging to treat the itch.

This new composition of matter can be used as a biomarker for itching signal conduction, thus improving treatment for chronic itch.

Stage of Research

Mouse model in-vivo tests have been performed

Applications

• Treatment of chronic itch

Key Advantages

• Treats the itch signaling pathway instead of the symptoms
• Can be administered orally

Patents

Patent application filed

Related Web Links – Mingzhou Zhou Profile